Chinese vaccines don’t have very high protection rates, says Gao Fu, Director of the China Center for Disease Control. Briefing journalists in Chengdu, he said the government was mulling mixing vaccines to boost their effectiveness. “It’s now under formal consideration whether we should use vaccines from different technical lines for the immunization process,” he acknowledged.
Other officials were quoted as saying that the medical community was working on mRNA-based vaccines that have reached the stage of clinical trials in China. Researchers in the UK are also studying the implications of mixing the Pfizer-BioNtech and the traditional AstraZeneca vaccine.
The Chinese Sinovac vaccine is reported having a little over 50 per cent efficacy when the Pfizer-BioNTech vaccine has 97 per cent efficacy.
